Blood Advances · 2025 · 15 citations · 24 references
Life SciencesHematologyImmunologyCancer ImmunologyClinical ImmunologyImmunotherapyB Cell BiologyB-cell ResponsesCancer ImmunotherapyCell-mediated ImmunityChimeric Antigen Receptor T-cell TherapyT Cell BiologyCd4 Positive T CellsCd4 T-cell DepletionHematologic Malignancy Car T-cell TherapyImmune Reconstitution KineticsMultiple Myeloma TherapyRelapsed Diffuse Large B-cell LymphomaRelapsed Multiple MyelomaT-cell Therapy
ABSTRACT: Chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable efficacy in treating relapsed and refractory (R/R) B-cell neoplasms, such as diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM). Despite its success, the long-term effects and sequelae of CAR T cells on the immune system remain underexplored. This study presents a 1-year follow-up analysis of 52 patients (42 with R/R DLBCL and 10 with R/R MM) treated with anti-CD19- and B-cell maturation antigen-targeted CAR T cells, focusing on immune reconstitution and infectious complications. Our findings reveal that CAR T-cell therapy leads to profound depletion of B and T cells. CD4+ T cells and CD19+ B cells exhibited impaired regeneration after treatment. Infections were more frequent during the first 30 days. In the short-term follow-up, density of infections within 100 days at risk was 1.8 in patients with DLBCL and 4.6 in patients with MM, with bacterial infections predominating in this early period after CAR T-cell infusion. In addition, we observed a shift to viral infections in the long-term follow-up, alongside with a decline in infection density to 0.1 in patients with DLBCL and 0.4 infections per 100 days at risk in patients with MM, respectively. Severe cytokine release syndrome was associated with a higher risk of late-onset infections. These findings highlight the importance of close monitoring and prophylactic measures in patients undergoing CAR T-cell therapy to reduce infection risks and enhance immune recovery.
24
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett et al. · New England Journal of Medicine · 2017 · 5.9K citations · Full text
Medicine, Hematology, Oncology +16
J. Peter Donnelly, Sharon Chen, Carol A. Kauffman et al. · Clinical Infectious Diseases · 2019 · 2.8K citations · Full text
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi, Larry D. Anderson, Nina Shah et al. · New England Journal of Medicine · 2021 · 2.4K citations · Full text
Medicine, Hematology, Oncology +17
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Stephen J. Schuster, Jakub Svoboda, Elise A. Chong et al. · New England Journal of Medicine · 2017 · 1.9K citations · Full text
Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani et al. · The Lancet · 2021 · 1.7K citations
Medicine, Hematology, Oncology +17